Mycophenolic Acid

證據等級: L5

預測適應症: 10 個

Mycophenolic Acid: From Transplant-Rejection Immunosuppression to Hemoglobinopathy

One-Sentence Summary

Mycophenolic acid (via its prodrug mycophenolate mofetil, MMF) is a purine-synthesis (IMPDH) inhibitor best established as an immunosuppressant for preventing organ transplant rejection. The TxGNN model predicts it may be effective for Hemoglobinopathy, with 27 clinical trials and 9 publications currently retrieved — but most of this evidence describes MMF only as a supportive immunosuppressive component of stem-cell transplant regimens, not as a direct treatment for the underlying blood disorder.

Quick Overview

Item	Content
Original Indication	Not available from Taiwan/US license data (drug is unmarketed, 0 licenses on file); literature within this pack (PMID 9399601) notes MMF is established for “prevention of acute renal allograft rejection when given in combination with cyclosporine and steroids”
Predicted New Indication	Hemoglobinopathy
TxGNN Prediction Score	99.60%
Evidence Level	L3
US Market Status	Not Marketed (未上市)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA field marked as a data gap). Based on information embedded in the retrieved evidence, mycophenolic acid is a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), which blocks the de novo purine synthesis pathway that lymphocytes depend on for proliferation. This underlies its use as an immunosuppressant in transplantation and autoimmune disease.

The link to hemoglobinopathy (sickle cell disease, thalassemia) is mechanistically indirect. Nearly all 27 retrieved trials are allogeneic hematopoietic stem cell transplantation (HSCT) studies, in which MMF is used as part of the graft-versus-host disease (GVHD) prophylaxis/conditioning regimen — not as a therapy that corrects the underlying globin-chain or red-cell defect. The rationale attached to this candidate explicitly flags this as a likely confounded association: TxGNN appears to have picked up the co-occurrence of “MMF” and “hemoglobinopathy” in transplant literature, rather than a genuine drug-disease treatment relationship. HSCT itself is curative for severe hemoglobinopathies, but MMF’s role there is supportive immunosuppression, not disease-modifying treatment of the hemoglobinopathy per se.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06872333	Phase 2	Recruiting	62	Allogeneic HSCT for high-risk hemoglobinopathies and red-cell transfusion-dependent disorders; MMF is part of the transplant regimen
NCT02435901	Phase 1/2	Completed	29	Reduced-intensity conditioning HSCT for sickle cell disease and β-thalassemia major with standard immunosuppressive medications
NCT01279616	Phase 2	Terminated	8	Reduced-toxicity immunosuppressive/myeloablative preparative regimen for unrelated-donor HSCT in severe sickle cell disease
NCT00489281	Phase 2	Terminated	43	Non-myeloablative conditioning and HLA-mismatched/matched bone marrow transplant for sickle cell anemia and other hemoglobinopathies
NCT01810588	Phase 2	Active, not recruiting	270	Optimal cord-blood selection strategy (IPA/NIMA matching) to improve haplo-cord transplant outcomes
NCT03249831	Phase 1	Active, not recruiting	3	Non-myeloablative conditioning and CD4+ T-cell-depleted haploidentical HSCT to induce mixed chimerism in sickle cell disease
NCT03171831	Phase 4	Unknown	30	Safety/efficacy of haploidentical HSCT for thalassemia major
NCT01350232	N/A	Terminated	2	Reduced-intensity allogeneic HSCT for sickle cell anemia from HLA-matched/partially-matched related donors; terminated after only 2 enrollees
NCT02867800	Phase 1	Completed	24	Abatacept added to standard GVHD prophylaxis (calcineurin inhibitor + methotrexate) after HSCT for pediatric sickle cell disease; MMF not the study drug
NCT04009525	Phase 4	Completed	823	Large multicenter prospective study of allo-HSCT efficacy in thalassemia major

Note: 17 additional trials were retrieved but not shown here (mostly ungraded/lower-relevance HSCT studies where MMF appears only as background GVHD prophylaxis).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39891881	2025	Review (PK modeling)	Eur J Drug Metab Pharmacokinet	Population-pharmacokinetics-based MMF dosing recommendations for pediatric thalassemia patients undergoing HSCT
26860634	2016	Cohort	Biol Blood Marrow Transplant	Alternative-donor HSCT with post-transplant cyclophosphamide is curative for nonmalignant disorders including hemoglobinopathies
36372358	2023	Cohort	Transplant Cell Ther	MMF used to boost immunosuppression in patients with declining mixed chimerism after thalassemia HSCT
18940682	2008	Cohort	Biol Blood Marrow Transplant	Reduced-intensity HSCT shows stable long-term donor engraftment in sickle cell disease
28578010	2017	Cohort (Phase 1)	Biol Blood Marrow Transplant	Unrelated cord blood transplant after reduced-intensity conditioning for severe sickle cell disease
29061531	2018	Cohort	Biol Blood Marrow Transplant	Unrelated-donor HSCT with post-transplant cyclophosphamide and MMF-based GVHD prophylaxis for severe sickle cell disease
17454192	2007	Cohort	Hematology (Amsterdam)	Risk factors for pure red cell aplasia after major ABO-incompatible allo-HSCT
15126382	2004	Review (limited relevance)	Genetics	General genetics/medicine commentary, not specific to MMF or hemoglobinopathy treatment
17180133	2007	Case Report (adverse event)	J Perinatol	Neonatal anemia and hydrops fetalis following maternal MMF use during pregnancy — a safety signal, not an efficacy finding

US Market Information

This drug currently has no marketed product license records in the dataset — Taiwan/US regulatory status is “Not Marketed” with 0 licenses on file.

Safety Considerations

Please refer to the package insert for safety information. No TFDA warnings, contraindications, or drug-interaction data are currently available for this candidate — this is flagged as a Blocking data gap (DG001) that prevents entry into the S1 safety pre-assessment stage.

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking-severity data gap exists (no TFDA warnings/contraindications), which by itself prevents starting the S1 safety review.
The mechanistic link for the top-ranked candidate (hemoglobinopathy) is very likely confounded: nearly all supporting trials/literature describe MMF as a background immunosuppressant within HSCT protocols, not as a treatment acting on the hemoglobinopathy’s underlying pathology.
The other 8 predicted indications in this evidence pack (migraine, chromosome 16p deletion, beta-thalassemia standalone, hereditary pyropoikilocytosis, GPI-deficiency hemolytic anemia, pyruvate kinase deficiency, antithrombin deficiency type 2) are all Evidence Level L5 with zero retrieved trials or literature — pure model prediction with no supporting evidence. Rheumatoid arthritis (rank 9, L3) has a terminated Phase 3 RCT with no conclusive results, and recent literature centers on RA-related interstitial lung disease off-label use rather than RA itself.

To proceed, the following is needed:

TFDA package insert data (warnings, contraindications) to clear the Blocking gap and enable S1 safety review
DrugBank MOA detail to support a rigorous mechanism-relevance analysis
Trial-level analysis that isolates MMF’s independent contribution from the overall HSCT conditioning regimen, to resolve the confounded-association concern
Drug-drug interaction (DDI) data, currently unavailable (query status: not_found)
Confirmed original-indication/regulatory baseline, since no Taiwan or US license records currently exist for this drug
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.